Junye Wang

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center · ORCID：0000-0002-7767-1860

发表论文 73 篇 · 总被引 2794 次 · h-index 20

代表论文

• USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer (2022 · Nature Communications · 被引 202)
• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 71)
• Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3) (2022 · 癌症：英文版 · 被引 60)
• A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol (2023 · Technology in Cancer Research & Treatment · 被引 20)
• Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study (2024 · EClinicalMedicine · 被引 10)
• Cuproptosis/OXPHOS tendency prediction of prognosis and immune microenvironment of esophageal squamous cell carcinoma: Bioinformatics analysis and experimental validation (2024 · Gene · 被引 10)